Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Atopic Dermatitis

22-Dec-2010 - Luxembourg

Creabilis SA announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis. CT327 is a novel topically applied TrkA kinase inhibitor developed using the Creabilis’ LSE (Low Systemic Exposure) technology. LSE technology creates new chemical entities with ideal characteristics for topical application (high local concentrations combined with low systemic exposure).

In the pilot efficacy study conducted in Switzerland, 15 atopic dermatitis patients (AD) were recruited, with eight treated topically with 0.1% CT327 [cream] twice daily for 15 days and seven receiving placebo. A clinically significant improvement in symptoms was seen after eight days of treatment with CT327 as measured by change in mEASI (modified eczema area and severity index) score from baseline. Onset of efficacy was seen at three to five days of treatment. The greatest patient-reported benefit was in night time itch, one of the most troublesome symptoms of atopic dermatitis. CT327 was shown to be safe and well tolerated with no serious adverse events and no reported site irritation.

CT327 is also currently in Phase IIa proof-of-concept clinical trials in psoriasis and pain. Further proof-of-concept clinical trials in inflammatory pain are planned.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances